Strikingly, however, Gpa33−/− mice are more susceptible than WT to DSS-induced loss of intestinal barrier function and severe colitis and, when DSS treatment is coupled with prior administration of the mutagen AOM, they develop significantly more and larger colon tumours. This evidence concerns the gene GPA33 and colitis.